Results 221 to 230 of about 1,089,379 (264)
Some of the next articles are maybe not open access.
Advances in cancer cytogenetics
Journal of Cellular Biochemistry, 1999As the end of the millenium approaches, recognition of the milestones achieved in the field of cancer cytogenetics is mandatory. With regard to cancer cytogenetics, the turning century can be divided in three main era: the pre-banding period that has posed important hypothesis and technical premises, the fruitful banding era that led to the discovery ...
G, Sozzi, M A, Testi, C M, Croce
openaire +2 more sources
Advances in cancer immunotherapy
Immunology Today, 1999Abstract Specific engagement of immune effector functions is a rapidly advancing field within experimental tumor therapy. A recent meeting**The 2nd International Dresden Symposium on Immunotherapy of Cancer was held at Dresden, Germany, on 12-13 June 1998.
D, Ockert +3 more
openaire +2 more sources
Suffering With Advanced Cancer
Journal of Clinical Oncology, 2007Purpose The alleviation of suffering is a central goal of palliative care, but little research has addressed the construct of suffering as a global experience of the whole person. We inquired into the sense of suffering among patients with advanced cancer to investigate its causes and correlates.
Keith G, Wilson +11 more
openaire +2 more sources
Advances in cancer chemotherapy
Journal of Chronic Diseases, 1961Abstract What is the role of the cancer chemotherapist in the conquest of malignant disease? Certainly the administration of chemicals to patients seems far removed from the basic research to discover the cure for cancer. Otto Warburg 5 has said, “The problem of cancer is not to explain life, but to discover the differences between cancer cells and ...
openaire +2 more sources
Current Treatment Options in Oncology, 2002
Despite advances in diagnosis and treatment, the prognosis for patients with stage III-IV laryngeal cancer is not significantly different than it was four decades ago [1]. This failure to improve survival is multifactorial and is likely linked to controversy surrounding optimal treatment regimens for a heterogeneous patient and tumor population. At the
Scott E, Strome, Eric C, Weinman
openaire +2 more sources
Despite advances in diagnosis and treatment, the prognosis for patients with stage III-IV laryngeal cancer is not significantly different than it was four decades ago [1]. This failure to improve survival is multifactorial and is likely linked to controversy surrounding optimal treatment regimens for a heterogeneous patient and tumor population. At the
Scott E, Strome, Eric C, Weinman
openaire +2 more sources
Hematology/Oncology Clinics of North America, 2002
When considered with other parameters, prognostic factors of survival in far advanced cancer patients are necessary to enable the doctor, the patient, and his or her relative to choose the most suitable clinical management and care setting. Original studies and literature reviews, albeit with methodologic difficulties, have identified the most ...
Maltoni M., Amadori D.
openaire +3 more sources
When considered with other parameters, prognostic factors of survival in far advanced cancer patients are necessary to enable the doctor, the patient, and his or her relative to choose the most suitable clinical management and care setting. Original studies and literature reviews, albeit with methodologic difficulties, have identified the most ...
Maltoni M., Amadori D.
openaire +3 more sources
Current Opinion in Oncology, 1993
Intravesical chemotherapy and immunotherapy are administered to patients with bladder cancer in the hope of decreasing the rate of recurrence and, more importantly, reducing the rate of progression. So far, bacille Calmette-Guérin is the only agent to decrease progression rate and thus increase survival.
openaire +2 more sources
Intravesical chemotherapy and immunotherapy are administered to patients with bladder cancer in the hope of decreasing the rate of recurrence and, more importantly, reducing the rate of progression. So far, bacille Calmette-Guérin is the only agent to decrease progression rate and thus increase survival.
openaire +2 more sources
European Journal of Oncology Nursing, 2010
Depression is one of the most common psychiatric diseases seen in patients with advanced cancer. It is not only an independent predictor of poor survival in advanced cancer but also reduces quality of life, reduces compliance with treatment and prolongs hospitalization.
Greg, Irving, Mari, Lloyd-Williams
openaire +2 more sources
Depression is one of the most common psychiatric diseases seen in patients with advanced cancer. It is not only an independent predictor of poor survival in advanced cancer but also reduces quality of life, reduces compliance with treatment and prolongs hospitalization.
Greg, Irving, Mari, Lloyd-Williams
openaire +2 more sources
Current Treatment Options in Oncology, 2001
Ovarian cancer spreads early in the disease into the abdomen. An en bloc resection of the tumor, according to surgical principle, is not possible in patients with high-stage ovarian cancer. At surgery, large pelvic tumor lesions are found together with multiple tumor lesions involving the omentum, bowel, and mesentery together with a diffuse peritoneal
openaire +2 more sources
Ovarian cancer spreads early in the disease into the abdomen. An en bloc resection of the tumor, according to surgical principle, is not possible in patients with high-stage ovarian cancer. At surgery, large pelvic tumor lesions are found together with multiple tumor lesions involving the omentum, bowel, and mesentery together with a diffuse peritoneal
openaire +2 more sources
Advances in Cancer Therapeutics
Current Pharmaceutical Design, 2021Shweta, Dang +2 more
openaire +2 more sources